Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Summary
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.
Official title: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
369
Start Date
2026-09-04
Completion Date
2030-09-04
Last Updated
2026-09-02
Healthy Volunteers
No
Conditions
Interventions
LBL-024 for Injection
intravenous infusion.
Bevacizumab injection
intravenous infusion.
Oxaliplatin injection
intravenous infusion.
Capecitabine tablets
Oral.
Fruquintinib Capsules
Oral.
Locations (10)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Shandong Cancer Hospital
Jinan, Shandong, China
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China